Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms

"We hope these data will support an EUA" (emergency use authorization) from the U.S. Food and Drug Administration, Regeneron Chief Scientific Officer George Yancopoulos said on a conference call. The treatment, REGN-COV2, is also being studied for use in hospitalized patients, and for prevention of infection in people who have been exposed to COVID-19. Regeneron declined to comment on when those trial results are expected.